Benefits
IBS women dose-ranging RCT (Whorwell 2006 PMID 16863564 PIVOTAL)
Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EMM 2006 (Am J Gastroenterol 101:1581-1590, PMID 16863564) — large-scale multicenter clinical trial. 362 female subjects with IBS (Rome II) randomized to placebo or 1 of 3 doses of B. infantis 35624 (1 million, 100 million, 10 billion CFU) once daily for 4 weeks. RESULTS: 100 MILLION CFU/day SIGNIFICANT IMPROVEMENT in abdominal pain/discomfort + bloating/distention + sense of incomplete evacuation + straining + urgency + passage difficulty. 1 MILLION CFU and 10 BILLION CFU showed NO BENEFIT. NARROW THERAPEUTIC WINDOW — DOSE-SPECIFIC efficacy. Foundational pivotal RCT — first probiotic with strain-specific dose-ranging IBS evidence. NCT00135031 registered.
IBS pilot study O'Mahony 2005 malted milk delivery
O'Mahony L et al. 2005 — pilot study delivering B. infantis 35624 via malted milk beverage at 10 billion CFU/day. Showed beneficial effects vs placebo. Foundational pilot supporting subsequent Whorwell 2006 confirmatory study. METHODOLOGICAL LIMITATIONS: inadequate participant allocation reporting, baseline imbalances suggestive of poor randomization, underpowered. Important to note as honest evidence-quality limitation. Ahead-of-its-time work that supported subsequent more rigorous trial.
Disease severity + quality of life (Sabaté 2022)
Sabaté JM, Iglicki F 2022 (World J Gastroenterol 28:732-744) — effect of Bifidobacterium longum 35624 on DISEASE SEVERITY and QUALITY OF LIFE in IBS patients. Recent confirmatory evidence with reclassified taxonomy. Multi-domain IBS benefits beyond pure symptom scores. Important quality-of-life evidence.
IBS-Constipation + IBS-Diarrhea + alternators efficacy (Whorwell 2006 subgroup)
Whorwell 2006 included IBS subtypes: 20.7% IBS-C, 55.5% IBS-D, 23.8% alternators. RESULTS: B. infantis 35624 efficacy across IBS subtypes. Important for clinical translation — many IBS treatments (e.g., antidiarrheals) work only for IBS-D; B. infantis 35624 supports broader IBS subtype application.
Inflammatory cytokine modulation (mechanism evidence)
B. infantis 35624 modulates HOST INFLAMMATORY PROCESSES BEYOND THE GUT (Gut Microbes 2013 4(4):325-339). Mechanism: gut-immune axis modulation reducing pro-inflammatory cytokines + supporting regulatory T cell function. Important systemic anti-inflammatory potential beyond pure gut symptom relief.
Strain-specificity (35624 distinct from other B. infantis)
B. infantis 35624 effects are STRAIN-SPECIFIC — not generalizable to other B. infantis strains. In O'Mahony 2005 trial, Lactobacillus comparison strain showed only 2nd-week composite symptom score improvement vs B. infantis 35624 4-week sustained improvement. Foundation principle: probiotic effects strain-specific not species-specific. Important for product selection.
Visceral antinociceptive effects (McKernan 2010 preclinical)
McKernan DP, Fitzgerald P, Dinan TG, Cryan JF 2010 (Neurogastroenterol Motil 22:1029-1035) — B. infantis 35624 displays VISCERAL ANTINOCICEPTIVE EFFECTS in rat model. Mechanism: gut-brain axis pain pathway modulation. Foundational preclinical evidence supporting clinical pain reduction observations in IBS trials.
Mechanism of action
Strain-specific immunomodulation (35624 distinct)
B. infantis 35624 effects are STRAIN-SPECIFIC. Different B. infantis strains produce different effects. Foundation principle. Important for clinical translation — generic 'probiotics' may not produce 35624 effects.
Gut-immune axis modulation (systemic)
Modulates host inflammatory processes BEYOND THE GUT (Gut Microbes 2013). Mechanism: gut-immune axis affecting systemic cytokines + regulatory T cell function. Distinguishes from probiotics with purely local gut effects.
Visceral antinociception
Visceral antinociceptive effects demonstrated in rat (McKernan 2010). Mechanism: gut-brain axis pain pathway modulation. Important for IBS abdominal pain reduction.
Adherence to human epithelial cells
Probiotic strain that adheres to human epithelial cells, can colonize and remain metabolically active in human GI tract. Mechanism for sustained effects vs transient gut transit.
Dose-specific narrow therapeutic window
Whorwell 2006 demonstrated NARROW DOSE-SPECIFIC efficacy: 100 million CFU/day effective, 1 million CFU not effective, 10 billion CFU not effective. Mechanism: hormesis-like or threshold-related effect. Important for product formulation precision.
Survives gastric acidity
Strain selected for ability to withstand gastric acidity + bile salts. Mechanism: efficient delivery to gut. Practical pharmaceutical advantage.
Clinical trials
Multicenter double-blind randomized placebo-controlled dose-ranging study (Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EMM 2006, Am J Gastroenterol 101:1581-1590, PMID 16863564). NCT00135031. Sponsor: Procter & Gamble.
362 female subjects with Rome II IBS. 2-week baseline → randomized to placebo or B. infantis 35624 1 million / 100 million / 10 billion CFU once daily for 4 weeks. Primary endpoint: abdominal pain score on 6-point Likert scale. Secondary: IBS symptom relief + quality of life.
100 MILLION CFU/day SIGNIFICANT IMPROVEMENT in abdominal pain/discomfort + bloating/distention + sense of incomplete evacuation + straining + urgency + passage difficulty over 4 weeks. 1 MILLION CFU and 10 BILLION CFU NO BENEFIT. NARROW THERAPEUTIC WINDOW — DOSE-SPECIFIC efficacy. AEs <5% withdrawal rate. INDUSTRY-SPONSORED (P&G) — important context but methodology rigorous (Whorwell + Quigley collaborators internationally recognized).
Pilot clinical trial (O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM 2005).
IBS patients. B. infantis 35624 vs Lactobacillus comparison vs placebo via MALTED MILK BEVERAGE at 10 billion CFU/day.
B. INFANTIS 35624 BENEFICIAL EFFECTS (4-week sustained improvement) vs Lactobacillus (only 2nd-week improvement). Foundational pilot supporting subsequent Whorwell 2006 confirmatory study. METHODOLOGICAL LIMITATIONS noted: inadequate participant allocation reporting, baseline imbalances suggestive of poor randomization, underpowered. Important to acknowledge as honest evidence-quality limitation.
Clinical trial (Sabaté JM, Iglicki F 2022, World J Gastroenterol 28:732-744).
IBS patients. Bifidobacterium longum 35624 (reclassified taxonomy from B. infantis 35624). Multiple duration courses with IBS-SSS measurement.
Effect on DISEASE SEVERITY and QUALITY OF LIFE in IBS patients. Recent confirmatory evidence with reclassified taxonomy. Multi-domain IBS benefits beyond pure symptom scores. Important quality-of-life evidence + recent reclassification to B. longum subsp. longum 35624.
About this ingredient
BIFIDOBACTERIUM INFANTIS 35624 is a SPECIFIC PROBIOTIC STRAIN commercialized by PROCTER & GAMBLE as ALIGN® (US) / Meta Align® (Australia) / BIFANTIS® / 35624™. Originally classified as Bifidobacterium infantis 35624; RECENTLY RECLASSIFIED as Bifidobacterium longum subsp. longum 35624 per updated taxonomic classification (Sabaté 2022 onwards). Strain-specific clinical evidence base distinct from generic B. infantis or B. longum supplements. PIVOTAL CLINICAL EVIDENCE: WHORWELL 2006 PMID 16863564 (Am J Gastroenterol 101:1581-1590) NCT00135031 — large-scale multicenter double-blind randomized placebo-controlled dose-ranging study sponsored by Procter & Gamble. 362 female subjects with Rome II IBS randomized to placebo or B. infantis 35624 1 million / 100 million / 10 billion CFU once daily for 4 weeks. RESULTS: 100 MILLION CFU/day SIGNIFICANT IMPROVEMENT in abdominal pain/discomfort + bloating/distention + sense of incomplete evacuation + straining + urgency + passage difficulty. 1 MILLION CFU and 10 BILLION CFU NO BENEFIT.
CRITICAL FINDING: NARROW THERAPEUTIC WINDOW — DOSE-SPECIFIC efficacy with U-shaped dose-response. <5% withdrawal due to AEs. O'MAHONY 2005 pilot study via malted milk beverage at 10 billion CFU/day showed beneficial effects (with methodological limitations: inadequate randomization, baseline imbalances, underpowered). SABATÉ 2022 (World J Gastroenterol 28:732-744) — disease severity + quality of life evidence with reclassified taxonomy. Whorwell 2006 IBS subtype distribution: 20.7% IBS-C, 55.5% IBS-D, 23.8% alternators — efficacy across subtypes important for clinical translation. PRECLINICAL: McKernan 2010 (Neurogastroenterol Motil 22:1029-1035) visceral antinociceptive effects in rat model. Gut Microbes 2013 4(4):325-339 — modulates HOST INFLAMMATORY PROCESSES BEYOND THE GUT.
MECHANISMS: STRAIN-SPECIFIC immunomodulation (distinct from other B. infantis strains); GUT-IMMUNE AXIS systemic modulation (beyond local gut effects); VISCERAL ANTINOCICEPTION (gut-brain axis pain pathway); adherence to human epithelial cells + colonization; DOSE-SPECIFIC NARROW THERAPEUTIC WINDOW (Whorwell 2006 hormesis-like effect); survives gastric acidity. EVIDENCE: 3/5 reflects: (1) WHORWELL 2006 PIVOTAL 362-women IBS dose-ranging RCT with statistically significant 100 million CFU/day efficacy, (2) O'MAHONY 2005 pilot study (with acknowledged methodological limitations), (3) SABATÉ 2022 recent confirmatory IBS QoL trial, (4) MCKERNAN 2010 preclinical visceral antinociceptive mechanism, (5) WELL-CHARACTERIZED strain-specific immunomodulation + dose-response, (6) HONEST FRAMING — only 1 of 3 doses showed benefit (NARROW WINDOW); significant IBS placebo response generally limits power, (7) multiple non-RCT studies + open-label trials supportive, (8) industry-sponsored evidence (Procter & Gamble) — important context but methodology rigorous (Whorwell + Quigley + Kiely + Shanahan APC Microbiome Cork collaborators), (9) RECENT TAXONOMIC RECLASSIFICATION to B. longum 35624 — important for product labeling consistency, (10) higher-evidence than typical Bifidobacterium probiotic supplement due to dose-ranging RCT methodology + multi-trial evidence base. SAFETY: Excellent — 4-week safety profile favorable in Whorwell 2006 + extensive Align® consumer use. Best positioned as: (a) IBS GLOBAL SYMPTOMS adjunct (Whorwell 2006 PIVOTAL evidence — 100 million CFU/day specifically), (b) ABDOMINAL PAIN/DISCOMFORT in IBS (primary endpoint significance), (c) BLOATING/DISTENTION in IBS, (d) IBS-C + IBS-D + ALTERNATORS subtype-broad applicability (Whorwell subtype evidence), (e) ALIGN® STANDARD branded product (1 billion CFU/day) — note: this exceeds Whorwell 2006 effective dose (100 million CFU); evidence supports specific narrow dose, (f) DAILY long-term use acceptable based on safety profile, (g) PREGNANCY: limited specific data, (h) IMMUNOCOMPROMISED: caution (applies to all probiotics), (i) ANTIBIOTIC USERS: take 2-3 hours apart, (j) higher-evidence than typical IBS probiotic supplement due to dose-ranging RCT + strain-specificity emphasis. Honest framing: B. infantis 35624 (Align®) has more rigorous evidence than typical IBS probiotic supplements — Whorwell 2006 multicenter dose-ranging RCT in 362 women is methodologically robust + first of its kind for probiotic strain-dose-ranging.
CRITICAL HONEST LIMITATION: ONLY 1 of 3 doses showed efficacy (100 million CFU/day specifically) — narrow therapeutic window. 1 million CFU NO benefit; 10 billion CFU NO benefit. IBS placebo response is substantial limiting some power. O'Mahony 2005 pilot had documented methodological limitations (inadequate randomization, baseline imbalances, underpowered). Recent Sabaté 2022 confirms efficacy with reclassified B. longum 35624 taxonomy. Procter & Gamble industry sponsorship warrants caveat — but methodology consistent with internationally recognized investigators (Whorwell, Quigley, Kiely, Shanahan). Product note: Align® consumer formulation provides ~1 billion CFU/day which EXCEEDS Whorwell 2006 effective dose (100 million CFU) — evidence supports specific narrow dose; whether higher consumer doses are equivalent or potentially less effective per Whorwell U-shape unknown. Reasonable IBS adjunct based on rigorous evidence — particularly compelling for those with multi-symptom IBS (abdominal pain + bloating + bowel difficulty) seeking strain-specific evidence-backed probiotic.